anti-Chromogranin A, mAb (23A1)
| Product Details | |
|---|---|
| Synonyms | CHGA |
| Product Type | Monoclonal Antibody |
| Properties | |
| Clone | 23A1 |
| Isotype | Mouse IgG2b κ |
| Immunogen/Antigen | Recombinant human CGA protein purified from E. coli. |
| Application |
Western Blot (1:2,000) |
| Crossreactivity | Human |
| Purity Detail | Ammonium sulfate precipitation. |
| Formulation | Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| Declaration | Manufactured by AbFrontier |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS | No |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Chromogranin A (CGA) was identified as a major soluble protein in adrenal medullary chromaffin granules. CHGA derived peptides are also known as Catestatin, Vasostatin-I,-II, Prochromacin, Pancreastatin and Parastatin. CGA and its processed products are involved in the biogenesis of densecore secretory granules and have a role in immunity against microbes, and function as potential markers for several types of tumors. They have also been implicated in neurodegenerative disorders and cardiovascular diseases such as a hypertension. CGA accumulates in the senile and preamyloid plaques of Alzheimer’s disease, in Lewy bodies of Parkinson’s disease, and in the swollen neurons of Pick’s disease. Pancreastatin strongly inhibits glucose induced insulin release from the pancreas.
1) Steinbrenner, H. et al (2006) Free Radic. Biol. Med. 40: 1513-1523. (General)
2) Burk, R.F. et al (2005) Annu. Rev. Nutr. 25: 215-235. (General)